- Home
- CGEN vs PROK Comparison
CGEN vs PROK Comparison
Compare CGEN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- PROK
- Stock Information
- Founded
- CGEN 1993
- PROK 2015
- Country
- CGEN Israel
- PROK United States
- Employees
- CGEN N/A
- PROK N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGEN Health Care
- PROK Health Care
- Exchange
- CGEN Nasdaq
- PROK Nasdaq
- Market Cap
- CGEN 135.6M
- PROK 126.8M
- IPO Year
- CGEN 2000
- PROK N/A
- Fundamental
- Price
- CGEN $1.47
- PROK $0.79
- Analyst Decision
- CGEN Strong Buy
- PROK Buy
- Analyst Count
- CGEN 1
- PROK 4
- Target Price
- CGEN $4.00
- PROK $5.00
- AVG Volume (30 Days)
- CGEN 268.4K
- PROK 1.1M
- Earning Date
- CGEN 05-19-2025
- PROK 05-09-2025
- Dividend Yield
- CGEN N/A
- PROK N/A
- EPS Growth
- CGEN N/A
- PROK N/A
- EPS
- CGEN N/A
- PROK N/A
- Revenue
- CGEN $27,864,000.00
- PROK $76,000.00
- Revenue This Year
- CGEN $11.81
- PROK N/A
- Revenue Next Year
- CGEN $28.37
- PROK N/A
- P/E Ratio
- CGEN N/A
- PROK N/A
- Revenue Growth
- CGEN N/A
- PROK N/A
- 52 Week Low
- CGEN $1.13
- PROK $0.46
- 52 Week High
- CGEN $2.66
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- CGEN 49.50
- PROK 45.47
- Support Level
- CGEN $1.13
- PROK $0.65
- Resistance Level
- CGEN $1.35
- PROK $1.18
- Average True Range (ATR)
- CGEN 0.11
- PROK 0.17
- MACD
- CGEN 0.03
- PROK 0.03
- Stochastic Oscillator
- CGEN 85.00
- PROK 45.97
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.